A Combination of Imatinib Mesylate and Pegylate Interferon a2a in Chronic-phase CML

Article

The goal of this study is to determine whether the addition of the drug pegylated interferon-a2a in combination with imatinib mesylate will allow the imatinib to target and kill the leukemic stem cells, hopefully putting the leukemia in remission without the need for continuous treatment.

Study Type: Interventional

Age/Sex Requirements: 18 years+ (None)

Sponsor: University of Michigan Cancer Center

Purpose: Imatinib mesylate is the standard first-line therapy for CML, controlling leukemia in a majority of patients by blocking the tyrosine kinase enzyme. However, imatinib mesylate does not kill the leukemic stem cells, and as a result is not curative. The goal of this study is to determine whether the addition of the drug pegylated interferon-a2a in combination with imatinib mesylate will allow the imatinib to target and kill the leukemic stem cells, hopefully putting the leukemia in remission without the need for continuous treatment.

Click here to access this third-party website.

Related Videos
A panel of 4 experts on HIV
A panel of 4 experts on HIV
Kelly Nichols, OD; Laura Periman, MD; and Mile Brujic, OD
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
A panel of 4 experts on asthma
A panel of 4 experts on asthma
© 2024 MJH Life Sciences

All rights reserved.